BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  Efficacy, Safety Concerns Quash Reata’s Alport Syndrome Drug

  The FDA said that the shared NDA documents did not show ample proof that bardoxolone methyl effectively slows down kidney function loss in patients with Alport syndrome.

  February 28, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Pause of GSK’s RSV Vaccine Trials in Pregnant Women Deepens

  The company is conducting analyses to understand safety data that had been gathered prior to the pausing of the three studies, NCT04605159, NCT04980391 and NCT05229068.

  February 28, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Biohaven Commits to New Drugs for Epilepsy and SMA

  Biohaven Pharmaceutical Holding announced the acquisition of Channel Bio and new licensing rights to a spinal muscle atrophy drug from Bristol Myers Squibb.

  February 28, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Business

  Celyad Trial Pause Another Setback for CAR-T in Solid Tumors

  Celyad announced that it is voluntarily pausing a clinical trial it’s conducting with Merck after reports of two patient deaths.

  February 28, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  Moderna’s Spikevax Faces Another Patent Challenge

  On Monday, Arbutus and Genevant filed a lawsuit against Moderna challenging patent infringement.

  February 28, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  A Platform for Hope in the Face of Rare and Uncommon Diseases

  Acrotech is looking to launch drugs with either improved efficacy and/or safety over currently available treatments in the oncology, dermatology, neuroscience and rare disease spaces.

  February 28, 2022

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Business

  DNA Damage Response Consortium Aims to Rapidly Develop Brain Cancer Therapies

  The National Brain Tumor Society is investing over $1 million in the DNA damage response consortium’s start. Here’s how this consortium will help researchers.

  February 28, 2022

   · 

  5 min read

   · 

  Abbey Glasure
• 

  Policy

  Judge Approves J&J’s Texas Two-Step Plan to Enable “Expeditious” Compensation

  The decision was intended to resolve the matter as swiftly as possible so that those who claimed to have been harmed by the product could receive expeditious compensation.

  February 28, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Deals

  Prioritize Programs and Preserve Resources to Weather 2022 Market Volatility

  That’s the advice for emerging growth life sciences companies in 2022, according to attorney Frank Rahmani, partner in the global life science and capital markets practice group at Sidley Austin LLP.

  February 28, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Drug Development

  Good News for Ocugen: COVID Vaccine Hold Lifted, New Clinical Trial Announced

  The FDA lifts its clinical hold on Ocugen’s COVID-19 vaccine, and Ocugen announces a clinical trial for the treatment of inherited retinal diseases.

  February 28, 2022

   · 

  2 min read

   · 

  Alex Keown